(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual revenue growth rate of 13.31% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.51%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.97%.
Aurinia Pharmaceuticals's revenue in 2025 is $260,111,000.On average, 3 Wall Street analysts forecast AUPH's revenue for 2025 to be $35,520,232,988, with the lowest AUPH revenue forecast at $35,322,788,669, and the highest AUPH revenue forecast at $35,697,932,875. On average, 4 Wall Street analysts forecast AUPH's revenue for 2026 to be $41,617,576,818, with the lowest AUPH revenue forecast at $37,448,605,837, and the highest AUPH revenue forecast at $46,832,476,171.
In 2027, AUPH is forecast to generate $50,199,165,069 in revenue, with the lowest revenue forecast at $45,951,874,509 and the highest revenue forecast at $58,788,387,835.